ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INSM Insmed Inc

25.81
0.54 (2.14%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,740,799
Bid Price 25.00
Ask Price 26.00
News -
Day High 25.955

Low
17.411

52 Week Range

High
32.00

Day Low 25.34
Company Name Stock Ticker Symbol Market Type
Insmed Inc INSM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.54 2.14% 25.81 17:30:00
Open Price Low Price High Price Close Price Prev Close
25.58 25.34 25.955 25.81 25.27
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
17,909 2,740,799 $ 25.66 $ 70,331,268 - 17.411 - 32.00
Last Trade Time Type Quantity Stock Price Currency
17:11:44 formt 48,671 $ 25.81 USD

Insmed (INSM) Options Flow Summary

Overall Flow

Bearish

Net Premium

-481k

Calls / Puts

0.00%

Buys / Sells

66.67%

OTM / ITM

25.00%

Sweeps Ratio

0.40%

Insmed Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.83B 148.49M - 305.21M -749.57M -5.05 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Insmed News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INSM Message Board. Create One! See More Posts on INSM Message Board See More Message Board Posts

Historical INSM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.2426.5423.52524.642,890,360-0.43-1.64%
1 Month27.0228.7123.52526.272,089,447-1.21-4.48%
3 Months28.8929.9123.52527.121,749,841-3.08-10.66%
6 Months25.3632.0023.0427.141,665,5660.451.77%
1 Year18.3132.0017.41125.131,435,9187.5040.96%
3 Years35.5036.9716.0423.751,210,142-9.69-27.30%
5 Years31.5945.4412.0924.811,138,664-5.78-18.30%

Insmed Description

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Your Recent History

Delayed Upgrade Clock